[go: up one dir, main page]

WO2021037532A1 - Procédé de rééducation de patients par exposition à des mélanges gazeux thérapeutiques - Google Patents

Procédé de rééducation de patients par exposition à des mélanges gazeux thérapeutiques Download PDF

Info

Publication number
WO2021037532A1
WO2021037532A1 PCT/EP2020/072359 EP2020072359W WO2021037532A1 WO 2021037532 A1 WO2021037532 A1 WO 2021037532A1 EP 2020072359 W EP2020072359 W EP 2020072359W WO 2021037532 A1 WO2021037532 A1 WO 2021037532A1
Authority
WO
WIPO (PCT)
Prior art keywords
patients
mixture
training
hypercapnic
hypoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2020/072359
Other languages
English (en)
Inventor
Egor EGOROV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP20761523.8A priority Critical patent/EP4017481A1/fr
Publication of WO2021037532A1 publication Critical patent/WO2021037532A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B23/00—Exercising apparatus specially adapted for particular parts of the body
    • A63B23/18—Exercising apparatus specially adapted for particular parts of the body for improving respiratory function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/0045—Means for re-breathing exhaled gases, e.g. for hyperventilation treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0208—Oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A61M2230/06—Heartbeat rate only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/30—Blood pressure
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B2213/00—Exercising combined with therapy
    • A63B2213/005—Exercising combined with therapy with respiratory gas delivering means, e.g. O2
    • A63B2213/006—Exercising combined with therapy with respiratory gas delivering means, e.g. O2 under hypoxy conditions, i.e. oxygen supply subnormal

Definitions

  • the invention relates to restorative and preventive medicine, and can be used to provide a delating effect on blood vessels and thus prevent the development of hypertension and the development of ischemic stroke and coronary heart disease, as well as in the correction of metabolic syndrome.
  • the disadvantage of this method is the impossibility of training patients using three gas mixtures - a hypoxic mixture, a hypoxic mixture with a hypercapnic component and a hyperoxic mixture with a hypercapnic component and, as a consequence, the low efficiency of training therapy for patients.
  • the physiological lumen of micro vessels is constantly maintained by maintaining the physiological (6-6.5% C02) concentration of carbon dioxide dissolved in the blood of the organism.
  • This substance is constantly produced in every cell of the body as the end product of the oxidation of carbohydrates (mainly glucose).
  • Carbon dioxide is released from the body through the lungs. On the way to the lungs, carbon dioxide persists in the blood for some time, playing the role of a natural regulator of the lumen of micro vessels, that is, restraining their narrowing.
  • the concentration of carbon dioxide (the norm is 6-6.5%) in arterial blood is a guarantee of the absence of persistent high blood pressure (BP) and thus is a factor that prevents the development of hypertension, ischemic stroke and coronary heart disease, vascular diseases of the brain, and contributing to the correction of metabolic syndrome (MS).
  • BP blood pressure
  • MS metabolic syndrome
  • Narrowing of micro vessels leads to a decrease in blood flow in the organs, that is, to a disruption of the normal blood supply to their tissues - ischemia.
  • ischemia leads to their oxygen starvation (tissue hypoxia). Due to the lack of oxygen during the narrowing of micro vessels, the cells cease to perform their functions in full.
  • Acute oxygen deficiency leads to massive cell death - organ infarctions, not only of the heart (myocardial infarction) or the brain (ischemic stroke), but also of other organs.
  • true treatment should be aimed at normalizing of blood circulation, that is, at eliminating the cause of hypertension (including normalizing the content of carbon dioxide in the body) - hypertension of all micro vessels, and not at artificially lowering blood pressure, which obviously leads to a deterioration in cerebral blood circulation, and even to a stroke, since arterial hypertension is just a symptom indicating a lack of blood flow in the organs and an overload of the heart muscle.
  • Metabolic syndrome is a combination of various metabolic disorders and / or diseases that are risk factors for the early development of atherosclerosis and its cardiovascular complications. Numerous studies have revealed the pathogenic relationship of visceral obesity, insulin resistance (as a consequence of hyperinsulinemia), lipid metabolism disorders, and arterial hypertension.
  • This so-called death quartet includes the most important components of the MS.
  • CVD cardiovascular disease
  • Hypocapnemia - a constant lack of carbon dioxide in the blood - the direct cause of arterial hypertension - a constant constriction (spasm) of arterioles and small arteries. While a person is young and moves relatively a lot, the intensity of his breathing corresponds to physiological norms and at rest is 2-4 liters per minute. With age, as a result of stress and because of a sedentary lifestyle, the intensity of respiration gradually increases and by the age of 50-60 it is already 8-12 liters per minute for most people, that is, it exceeds the norm by 2-3 times. Excessive ventilation of the lungs leads to increased leaching of carbon dioxide from arterial blood. Thus, the cause of hypertension is a low content of carbon dioxide in arterial blood - hypocapnemia.
  • the atmospheric air contains 0.03% of carbon dioxide, in the air we exhale, there is about 3% of carbon dioxide, that is, about 100 times more than in the atmosphere.
  • a natural antispasmodic that is, a substance that resists hypertension - spasm of the smallest arteries and arterioles. Outwardly, this is expressed in an increase in the intensity of breathing.
  • the resulting arterial hypertension - narrowing of all micro vessels impairs the blood supply to all organs. This is the essence of hypertension.
  • Restoring the body's ability to maintain the optimal concentration of carbon dioxide in the blood is a necessary condition and often the only way to get rid of both many diseases and drugs that destroy the body.
  • the aim of the invention is to train patients with therapeutic gas mixtures.
  • the technical result of the invention is to increase the effectiveness of training therapy for patients.
  • the method includes alternately supplying of gas mixtures to patients during respiratory training procedures, each procedure consists of 3-15 cycles of exposure of the patients to the therapeutic gas mixtures, one cycle is exposure to a hypoxic mixture or a hypoxic mixture with a hypercapnic component for 1-30 minutes, then the exposure to a hyperoxic mixture with a hypercapnic component for the duration of 1-30 minutes, while every 3-5 procedures there is an increase in the carbon dioxide content in the cycle mixtures by 0.5-1% and reduction of oxygen content in a hypoxic mixture or a hypoxic mixture with a hypercapnic component by 0.5-1%.
  • Three gas mixtures in an alternating sequence are supplied to the patient during training for therapeutic purposes, varying the composition of the therapy regimens depending on the individual condition of the patient, which makes it possible to increase the effectiveness of the patient's training therapy.
  • hypoxia-hypercapnia method is effective in such diseases as arterial hypertension, coronary heart disease, neurocirculatory asthenia, arrhythmias, allergic dermatitis, type 2 diabetes mellitus, anemia, climacteric syndrome, thyroid diseases, periodontitis, migraine, Alzheimer's disease, bronchial asthma, chronic obstructive pulmonary disease (COPD), psoriasis, neurodermatitis, obesity, metabolic syndrome, allergies, dementia, chronic fatigue syndrome, as well as for training athletes in high-performance sports.
  • diseases as arterial hypertension, coronary heart disease, neurocirculatory asthenia, arrhythmias, allergic dermatitis, type 2 diabetes mellitus, anemia, climacteric syndrome, thyroid diseases, periodontitis, migraine, Alzheimer's disease, bronchial asthma, chronic obstructive pulmonary disease (COPD), psoriasis, neurodermatitis, obesity, metabolic syndrome, allergies, dementia, chronic fatigue syndrome, as well as for training athletes in high
  • hypoxia in the processes of regulation of physiological functions, within certain limits, reinforce each other.
  • hypoxia essentially does not stimulate respiration.
  • the ventilation apparatus reacts more to the same level of carbon dioxide than under normoxia.
  • hyperoxia the effect of the hypercapnic factor is weakened, but the reoxygenation process is enhanced.
  • hypoxic mixture with a hypercapnic component (7-18% oxygen, 0.1-7% carbon dioxide)
  • hyperoxic mixture with a hypercapnic component (22-40% oxygen, 0.1-7% carbon dioxide)
  • hypoxic mixture (7- 18% oxygen).
  • the patient's individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (breathing a hypoxic gas mixture) with 12% oxygen content with every minute monitoring of heart rate (heart rate) and Sa02 (peripheral saturation - blood oxygen saturation). If the test is well tolerated by the patient, there is a decrease in a 10-minute hypoxic cycle in the saturation of hemoglobin with oxygen to no more than 82%, and the maximum heart rate is no more than 110 beats / min. In case of normal tolerance of the test, training begins with 7-18% oxygen in the therapeutic gas mixture.
  • the percentage of oxygen in the therapeutic mixture is selected so that Sa02 by the end of the fourth minute of breathing with the therapeutic mixture is within 82% -85% and the heart rate does not exceed 110 beats / min.
  • the Stange test is determined in patients - the time of holding the breath after exhalation. When a breath holding is less than 20 seconds, the first 5-10 training procedures begin with the supply of a hypoxic mixture and a hyperoxic mixture with a hypercapnic component. Later, after 5-10 training procedures, a hypoxic mixture with a hypercapnic component and a hyperoxic mixture with a hypercapnic component are served.
  • the training of patients begins with the supply of a hypoxic mixture with a hypercapnic component and a hyperoxic mixture with a hypercapnic component.
  • the training cycle begins with the supply through the mask to the patient of a hypoxic mixture with an oxygen content of 7-18% for 1-30 minutes or a hypoxic mixture with a hypercapnic component with an oxygen content of 7-18% and carbon dioxide of 0.1-7% for 1-30 minutes, then a hyperoxic mixture with a hypercapnic component with an oxygen content of 22-40% and carbon dioxide 0.1-7% for 1-30 minutes.
  • the intensity of hypoxia will be increased by decreasing the oxygen concentration in the respiratory mixture (hypoxic mixture or hypoxic mixture with a hypercapnic component) by 0.5-1% in combination with an increase in hypercapnia by 0.5-1% (an increase in the concentration of carbon dioxide).
  • the concentration of carbon dioxide increases by 0.5-1% every 3-5 procedures in a hypoxic mixture with a hypercapnic component and in a hyperoxic mixture with a hypercapnic component.
  • the effectiveness of the proposed training method is assessed by the dynamics of vegetative indicators recorded before and after each session - heart rate and Sa02 (in the dynamics of each session), blood pressure, parameters of heart rate variability.
  • Alternating supply of a hypoxic mixture or a hypoxic mixture with a hypercapnic component and a hyperoxic mixture in combination with hypercapnia in normobaric conditions use of normobaric hypoxic intervals, alternation with hyperoxic intervals (in combination with hypercapnia) and a stepwise increase in the dose of carbon dioxide both in the hypoxic and in the hyperoxic phases of training by 0.5-1% every 3-5 procedures increases the body's resistance to hypercapnia (every 3-5 procedures there is an increase in carbon dioxide in the cycle mixtures by 0.5-1%) and increase the body ' s resistance to hypoxia (every 3-5 procedures there is a decrease in oxygen in a hypoxic mixture or a hypoxic mixture with a hypercapnic component by 0.5-1%) and thus increases the effectiveness of training therapy for patients.
  • hypoxic-hyperoxic training with a hypercapnic component has the expected training effects - an increase in resistance to hypoxia according to subjective self-reports and objective criteria - the dynamics of Sa02 and heart rate, the values of the Stange test, normalization of blood pressure and - that significantly - biochemical parameters: a decrease in glycaemia and fasting insulinemia, which ensured a decrease in the phenomena of insulin resistance and thus increased the effectiveness of training therapy in patients.
  • the main group breathed a hypoxic mixture containing 7-18% oxygen for the duration of 1-30 minutes.
  • a hyperoxic mixture with a hypercapnic component containing 22-40% oxygen, 0.1-7% carbon dioxide was fed through the mask.
  • the intensity of hypoxia was increased, reducing the oxygen content by 0.5-1%.
  • hypercapnia in a hyperoxic respiratory mixture with a hypercapnic component was increased in parallel, increasing the carbon dioxide content by 0.5-1%, while the oxygen content was 22-40%.
  • an increase in hypoxia by reducing the oxygen concentration by the next 0.5-1% in combination with an increase in hypercapnia by 0.5-1% of the carbon dioxide content That is, an increase in the concentration of carbon dioxide by 0.5-1% every 3-5 procedures in a hyperoxic mixture with a hypercapnic component.
  • a total of 15 procedures were carried out 3-4 times a week. Each procedure consists of 3-15 cycles.
  • the depth of the hypoxic effect depended on the hypoxic test (the patient's individual sensitivity to oxygen); switching to hyperoxia with a hypercapnic component was carried out automatically.
  • Stange's test anamnesis, anthropometric measurements (body weight), biochemical blood tests with determination of the level of total cholesterol, high density lipoproteins, triglycerides, fasting plasma glucose and insulin, the body mass index, atherogenic coefficient and insulin resistance index, body impedance measurement with determination of active cell mass (in kg and%), muscle mass (in kg and%), and fat mass (in kg and%), blood pressure and heart rate were measured before and after the procedure.
  • the Student's test and the Mann-Whitney test were used.
  • the breath holding time (Stange test) after the course increased on average by 1.5 times: from 27.6 ⁇ 0.81 to 41.4 ⁇ 1.24 (p ⁇ 0.001), which indicates an increase in the capabilities of the respiratory system and an increase in organism resistance.
  • testing patients training with a hypoxic mixture with a hypercapnic component and a hyperoxic mixture with a hypercapnic component were selected - men and women aged 22-60 years with metabolic syndrome, including alimentary obesity 1-3 degrees, type 2 diabetes mellitus, arterial hypertension and dyslipidemia. Patients received basic therapy (diet therapy, dosed physical activity, tableted antihyperglycemic drugs) according to the pathology.
  • patients of the main group received a hypoxic mixture with a hypercapnic component and a hyperoxic mixture with a hypercapnic component to correct the individual components of the metabolic syndrome.
  • the main group breathed with a hypoxic mixture with a hypercapnic component containing 7-18% oxygen and 0,1-7% carbon dioxide for 1-30 minutes, then a hyperoxic mixture with a hypercapnic component was fed through a mask with a content of 22-40% oxygen and 0, 1-7% carbon dioxide for 1-30 minutes.
  • the intensity of hypoxia was increased, reducing the oxygen content by 0.5-1% in combination with an increase in hypercapnia, increasing the carbon dioxide content by 0.5-1% in the hypoxic breathing mixture with a hypercapnic component.
  • hypercapnia in a hyperoxic respiratory mixture with a hypercapnic component was increased in parallel, increasing the carbon dioxide content by 0.5-1%, while the oxygen content was 22-40%.
  • an increase in hypoxia by reducing the oxygen concentration by the next 0.5-1% in combination with an increase in hypercapnia by 0.5-1% of the carbon dioxide content.
  • the depth of the hypoxic effect depended on the hypoxic test (the patient's individual sensitivity to oxygen); switching to hyperoxia with a hypercapnic component was carried out automatically.
  • Stange's test anamnesis, anthropometric measurements (body weight), biochemical blood tests with determination of the level of total cholesterol, high density lipoproteins, triglycerides, fasting plasma glucose and insulin, the body mass index, atherogenic coefficient and insulin resistance index, body impedance measurement with determination of active cell mass (in kg and%), muscle mass (in kg and%), and fat mass (in kg and%), blood pressure and heart rate were measured before and after the procedure.
  • the Student's test and the Mann-Whitney test were used.
  • the concentration of total cholesterol decreased by 8.5% (p ⁇ 0.01), while the level of high-density lipoproteins slightly increased (by an average of 10.2%), which provided a significant decrease in the atherogenic coefficient (by 20.5%; p ⁇ 0.001).
  • the concentration of triglycerides in the blood decreased, which indicates the normalizing effect of training patients with therapeutic gas mixtures on lipid metabolism.
  • breath holding time (Stange's test) after the course of interval training of patients with therapeutic gas mixtures increased by an average of 1.7 times: from 27.6 ⁇ 0.81 to 47.8 ⁇ 1.34 (p ⁇ 0.001), which indicates an increase the possibilities of the respiratory system and an increase in the body's resistance to hypoxia and hypercapnia.
  • the method of training patients with therapeutic gas mixtures is effective in correcting individual components of the metabolic syndrome, preventing the development of metabolic and cardiovascular complications.
  • the method of training patients with therapeutic mixtures increases the effectiveness of training therapy for patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne la médecine réparatrice et préventive. Le procédé de rééducation de patients par exposition à des mélanges gazeux thérapeutiques comprend la fourniture alternée de mélanges à des patients pendant des procédures de rééducation respiratoire. Chaque procédure consiste en 3 à 15 cycles d'exposition de patients à des mélanges gazeux thérapeutiques. L'invention permet d'augmenter l'efficacité de la thérapie de rééducation de patients.
PCT/EP2020/072359 2019-08-23 2020-08-10 Procédé de rééducation de patients par exposition à des mélanges gazeux thérapeutiques Ceased WO2021037532A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20761523.8A EP4017481A1 (fr) 2019-08-23 2020-08-10 Procédé de rééducation de patients par exposition à des mélanges gazeux thérapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RURU2019126739 2019-08-23
RU2019126739A RU2716478C9 (ru) 2019-08-23 2019-08-23 Способ получения лечебных газовых смесей и способ тренировки пациентов лечебными газовыми смесями

Publications (1)

Publication Number Publication Date
WO2021037532A1 true WO2021037532A1 (fr) 2021-03-04

Family

ID=69898439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/072359 Ceased WO2021037532A1 (fr) 2019-08-23 2020-08-10 Procédé de rééducation de patients par exposition à des mélanges gazeux thérapeutiques

Country Status (3)

Country Link
EP (1) EP4017481A1 (fr)
RU (1) RU2716478C9 (fr)
WO (1) WO2021037532A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2067440C1 (ru) * 1992-11-02 1996-10-10 Николай Григорьевич Триняк Способ повышения физической работоспособности спортсменов
WO2002004041A2 (fr) * 2000-07-07 2002-01-17 Agadjhanian Nicolai Alexandrov Procede pour ameliorer les capacites d'adaptation et de compensation de l'organisme humain
RU2015142262A (ru) * 2015-10-01 2017-04-13 Общество С Ограниченной Ответственностью "Селлэйр Констракшн" Способ получения и подачи гипоксической и гиперкапнически-гипероксической смесей для проведения лечебных процедур и устройство для его осуществления

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503643A (ja) * 1993-09-22 1996-04-23 トラドテック エス アー 吸気内酸素欠乏用ガス混合物を製造する方法及び装置
US5558698A (en) * 1993-10-25 1996-09-24 Membrane Technology And Research, Inc. Acid gas fractionation process
RU2301686C1 (ru) * 2006-05-26 2007-06-27 Татьяна Николаевна Цыганова Аппарат для гипо-, гиперокситерапии
RU2414250C2 (ru) * 2008-12-31 2011-03-20 Общество с ограниченной ответственностью "ВНИИМИ" Устройство для создания гипоксических и гипероксических смесей
CA3018631C (fr) * 2016-05-13 2021-03-02 Lynntech, Inc. Dispositif d'entrainement a l'hypoxie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2067440C1 (ru) * 1992-11-02 1996-10-10 Николай Григорьевич Триняк Способ повышения физической работоспособности спортсменов
WO2002004041A2 (fr) * 2000-07-07 2002-01-17 Agadjhanian Nicolai Alexandrov Procede pour ameliorer les capacites d'adaptation et de compensation de l'organisme humain
RU2015142262A (ru) * 2015-10-01 2017-04-13 Общество С Ограниченной Ответственностью "Селлэйр Констракшн" Способ получения и подачи гипоксической и гиперкапнически-гипероксической смесей для проведения лечебных процедур и устройство для его осуществления
RU2625594C2 (ru) 2015-10-01 2017-07-17 Общество С Ограниченной Ответственностью "Селлэйр Констракшн" Способ получения и подачи гипоксической и гиперкапнически-гипероксической смесей для проведения лечебных процедур и устройство для его осуществления

Also Published As

Publication number Publication date
EP4017481A1 (fr) 2022-06-29
RU2716478C1 (ru) 2020-03-11
RU2716478C9 (ru) 2020-09-14

Similar Documents

Publication Publication Date Title
Gorman et al. Ventilatory physiology of patients with panic disorder
Dripps et al. The respiratory and circulatory response of normal man to inhalation of 7.6 and 10.4 per cent CO2 with a comparison of the maximal ventilation produced by severe muscular exercise, inhalation of CO2 and maximal voluntary hyperventilation
Bernardi et al. Hypoxic ventilatory response in successful extreme altitude climbers
Srivastava et al. Influence on alternate nostril breathing on cardiorespiratory and autonomic functions in healthy young adults
Gallagher Exercise and chronic obstructive pulmonary disease
Chaudhary et al. Effects of Buteyko breathing technique on physiological and psychological parameters among University football players
Woorons et al. Exercise with end-expiratory breath holding induces large increase in stroke volume
Helfer et al. Respiratory muscle training and exercise endurance at altitude
Hursh et al. Inspiratory muscle training: improvement of exercise performance with acute hypoxic exposure
Wheatley et al. Effects of exercise intensity compared to albuterol in individuals with cystic fibrosis
Motley The use of oxygen in comatose states
Oda et al. Rapid respiratory transition at birth as evaluated by electrical activity of the diaphragm in very preterm infants supported by nasal CPAP
Boässon et al. Arrhythmogenicity of scuba diving Holter monitoring in a hyperbaric environment.
RU2255723C2 (ru) Способ проведения длительной искусственной вентиляции легких
WO2021037532A1 (fr) Procédé de rééducation de patients par exposition à des mélanges gazeux thérapeutiques
Wheelock et al. Endurance and resistance respiratory muscle training and aerobic exercise performance in hypobaric hypoxia
Bassovitch et al. Equipment and regimes for intermittent hypoxia therapy
Lang Blood pressure and heart rate changes during apnoea testing with or without CO2 insufflation
EA022674B1 (ru) Способ лечения митохондриальных расстройств
RU2161476C2 (ru) Немедикаментозный способ реабилитации, профилактики и повышения функционального резерва организма человека
da L. Goulart et al. Influence of expiratory positive airway pressure on cardiac autonomic modulation at rest and in submaximal exercise in COPD patients
RU2841456C1 (ru) Способ адаптационно-восстановительного воздействия на организм человека
Bickerman et al. The effect of breathing 100 per cent oxygen in pulmonary emphysema: correlation of clinical improvement with changes in pulmonary ventilation
Ved et al. A Study to Compare the Effect of Inverse Ratio Breathing and Diaphragmatic Breathing on Pulmonary Functions in Obese Female–An Interventional Study
Zavorsky et al. Acute hypervolaemia improves arterial oxygen pressure in athletes with exercise-induced hypoxaemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20761523

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020761523

Country of ref document: EP

Effective date: 20220323